Tudor Investment Corp Et Al Lowers stake in Hologic (HOLX)

Hologic (HOLX) : Tudor Investment Corp Et Al reduced its stake in Hologic by 8.44% during the most recent quarter end. The investment management company now holds a total of 1,200,000 shares of Hologic which is valued at $43,740,000 after selling 110,684 shares in Hologic , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Hologic makes up approximately 1.58% of Tudor Investment Corp Et Al’s portfolio.

Other Hedge Funds, Including , United Services Automobile Association reduced its stake in HOLX by selling 118,699 shares or 9.36% in the most recent quarter. The Hedge Fund company now holds 1,148,835 shares of HOLX which is valued at $41,875,036. Hologic makes up approx 0.14% of United Services Automobile Association’s portfolio.Teachers Advisors boosted its stake in HOLX in the latest quarter, The investment management firm added 177,283 additional shares and now holds a total of 499,587 shares of Hologic which is valued at $19,324,025. Hologic makes up approx 0.03% of Teachers Advisors’s portfolio.Baldwin Brothers Incma reduced its stake in HOLX by selling 1,193 shares or 2.93% in the most recent quarter. The Hedge Fund company now holds 39,532 shares of HOLX which is valued at $1,529,098. Hologic makes up approx 0.29% of Baldwin Brothers Incma’s portfolio. Strategy Asset Managers added HOLX to its portfolio by purchasing 70,567 company shares during the most recent quarter which is valued at $2,516,419. Hologic makes up approx 0.58% of Strategy Asset Managers’s portfolio.Malaga Cove Capital boosted its stake in HOLX in the latest quarter, The investment management firm added 4,169 additional shares and now holds a total of 74,269 shares of Hologic which is valued at $2,857,128. Hologic makes up approx 2.09% of Malaga Cove Capital’s portfolio.

Hologic closed down -0.21 points or -0.54% at $38.37 with 19,16,246 shares getting traded on Monday. Post opening the session at $38.52, the shares hit an intraday low of $38 and an intraday high of $38.69 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Hologic reported $0.52 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $0.50. The company had revenue of $726.80 million for the quarter, compared to analysts expectations of $721.76 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.